Mast cell changes in experimental diabetes: Focus on attenuation of allergic events

Memorias do Instituto Oswaldo Cruz

Volumn 100, Issue SUPPL. 1, 2005, Pages 121-125

  Carvalho, Vinicius F ^a   Barreto, Emiliano O ^a   Cordeiro, Renato S B ^a   Lagente, Vincent ^b   Martins, Marco A ^a   E Silva, Patrícia M R ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Allergy; Diabetes; Glucocorticoids; Mast cells

Indexed keywords

ALLERGEN; GLUCOCORTICOID; INSULIN; MIFEPRISTONE; STEROID;

ADRENALECTOMY; ALLERGIC REACTION; ALLERGY; ALLOXAN DIABETES MELLITUS; ANAPHYLAXIS; ASTHMA; ATOPY; CELL COUNT; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE EXACERBATION; DOWN REGULATION; EXPERIMENTAL DIABETES MELLITUS; HUMAN; INFLAMMATION; MAST CELL; NONHUMAN; PREVALENCE; SYMPTOM;

EID: 18844424690     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762005000900021     Document Type: Conference Paper

References (66)

1. Abbas AK, Murphy KM, Sher A 1996. Functional diversity of helper T lymphocytes. Nature 383: 787-793.
2. Akamine EH, Hohman TC, Nigro D, Carvalho MH, de Cassia Tostes R, Fortes ZB 2003. Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther 304: 1236-1242.
3. Atkinson MA, Maclaren NK 1994. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331: 1428-1436.
4. Barnes PJ 2004. New drugs for asthma. Nat Rev Drug Discov 3: 831-844.
5. Barreto EO, Carvalho VF, Lagente V, Lugnier C, Cordeiro RS, Martins MA, e Silva PM 2004. Increased levels of cyclic adenosine monophosphate contribute to the hyporesponsiveness of mast cells in alloxan diabetes. Int Immunopharmacol 4: 755-762.
6. Bell GI, Polonsky KS 2001. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 414: 788-791.
7. Bottini N, Fontana L 1999. Asthma and diabetes. Lancet 354: 515-516.
8. Braun CM, Huang SK, Bashian GG, Kagey-Sobotka A, Lichtenstein LM, Essayan DM 1997. Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses. J Allergy Clin Immunol 100: 400-407.
9. Brownlee M 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
10. Cameron OG, Kronfol Z, Greden JF, Carroll BJ 1984. Hypothalamic- pituitary-adrenocortical activity in patients with diabetes mellitus. Arch Gen Psychiatry 41: 1090-1095.
11. Cardwell CR, Shields MD, Carson DJ, Patterson CC 2003. A meta-analysis of the association between childhood type 1 diabetes and atopic disease. Diabetes Care 26: 2568-2574.
12. Carvalho VF, Barreto EO, Diaz BL, Serra MF, Azevedo V, Cordeiro RS, Martins MA, e Silva PM 2003. Systemic anaphylaxis is prevented in alloxan-diabetic rats by a mechanism dependent on glucocorticoids. Eur J Pharmacol 472: 221-227.
13. Cavalher-Machado SC, de Lima WT, Damazo AS, de Frias Carvalho V, Martins MA, e Silva PM, Sannomiya P 2004. Down-regulation of mast cell activation and airway reactivity in diabetic rats: role of insulin. Eur Respir J 24: 552-558.
14. Chan O, Inouye K, Riddell MC, Vranic M, Matthews SG 2003. Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinol 28: 87-102.
15. Chan O, Inouye K, Vranic M, Matthews SG 2002. Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetes is associated with reduced stress responsiveness and decreased pituitary and adrenal sensitivity. Endocrinology 143: 1761-1768.
16. de Oliveira Barreto E, de Frias Carvalho V, Diaz BL, Balduino A, Cordeiro RS, Martins MA, Rodrigues e Silva PM 2003. Adoptive transfer of mast cells abolishes the inflammatory refractoriness to allergen in diabetic rats. Int Arch Allergy Immunol 131: 212-220.
17. Dhar HL, Sanyal RK, West GB 1967. Anaphylactic shock and the blood sugar level. J Pharm Pharmacol 19: 699-700.
18. Diaz B, Barreto E, Cordeiro R, Perretti M, Martins M, Silva P 2001. Enhanced serum glucocorticoid levels mediate the reduction of serosal mast cell numbers in diabetic rats. Life Sci 68: 2925-2932.
19. Diaz BL, Serra MF, Alves AC, Pires AL, Correa FM, Cordeiro RS, Martins MA, e Silva PM 1996. Alloxan diabetes reduces pleural mast cell numbers and the subsequent eosinophil influx induced by allergen in sensitized rats. Int Arch Allergy Immunol 111: 36-43.
20. Diaz BL, Serra MF, Barreto EO, Cordeiro RS, Martins MA, e Silva PM 1997. Antigen-induced pleural eosinophilia is suppressed in diabetic rats: role of corticosteroid hormones. Mem Inst Oswaldo Cruz 92 (Suppl II): 219-222.
21. Douek IF, Leech NJ, Gillmor HA, Bingley PJ, Gale EA 1999. Children with type-1 diabetes and their unaffected siblings have fewer symptoms of asthma. Lancet 353: 1850.
22. Finotto S, Mekori YA, Metcalfe DD 1997. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 99: 1721-1728.
23. Fortes ZB, Garcia Leme J, Scivoletto R 1984. Vascular reactivity in diabetes mellitus: possible role of insulin on the endothelial cell. Br J Pharmacol 83: 635-643.
24. Fortes ZB, Farsky SP, Oliveira MA, Garcia-Leme J 1991. Direct vital microscopic study of defective leukocyte-endothelial interaction in diabetes mellitus. Diabetes 40: 1267-1273.
25. Ganley OH 1962. Studies on the prevention of sensitization by Bordetella pertussis in alloxan diabetic mice. Can J Biochem Physiol 40: 1179-1183.
26. Garcia Leme J, Farsky SP 1993. Hormonal control of inflammatory response. Mediators of Inflammation 2: 181-198.
27. Garcia-Leme J, Bohm GM, Migliorini RH, de Souza MZ 1974. Possible participation of insulin in the control of vascular permeability. Eur J Pharmacol 29: 298-306.
28. Garcia Leme J, Hamamura L, Migliorini RH, Leite MP 1973. Experimental diabetes and inflammatory reactions in the rat. Agents Actions 3: 380-381.
29. Gaulton GN, Schwartz JL, Eardley DD 1985. Assessment of the diabetogenic drugs alloxan and streptozotocin as models for the study of immune defects in diabetic mice. Diabetologia 28: 769-775.
30. Goldsmith P, McGarity B, Walls AF, Church MK, Millward-Sadler GH, Robertson DA 1990. Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Dig Dis Sci 35: 1409-1413.
31. Hoet JJ, Tripathy BB 1996. Report of the International Workshop on types of Diabetes Peculiar to the Tropics. Diabetes Care 19: 1014.
32. Isoniemi HM, Ahonen J, Tikkanen MJ, von Willebrand EO, Krogerus L, Eklund BH, Hockerstedt KV, Salmela KE, Hayry PJ 1993. Long-term consequences of different immunosuppressive regimens for renal allografts. Transplantation 55: 494-499.
33. Klip A, Marette A, Dimitrakoudis D, Ramlal T, Giacca A, Shi ZQ, Vranic M 1992. Effect of diabetes on glucoregulation. From glucose transporters to glucose metabolism in vivo. Diabetes Care 15: 1747-1766.
34. Larkin JG, Frier BM, Ireland JT 1985. Diabetes mellitus and infection. Postgrad Med J 61: 233-237.
35. Lima MC, Martins MA, Perez SA, Peixoto JM, Silva PM, Cordeiro RS 1990. Kinetics of pleural exudation and cellular alterations induced by antigen in actively sensitized rats. Braz J Med Biol Res 23: 857-860.
36. Lima MC, Martins MA, Perez SA, Silva PM, Cordeiro RS, Vargaftig BB 1991. Effect of azelastine on platelet-activating factor and antigen-induced pleurisy in rats. Eur J Pharmacol 197: 201-207.
37. Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R 1993. Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 36: 84-87.
38. Lukens FDW 1948. Alloxan diabetes. Physiol Rev 28: 304-328.
39. Meehan WP, Leedom LJ, Henry JP 1988. Diabetes mellitus, adrenal function and the defeat response. Acta Physiol Scand 571 (Suppl.): 117-128.
40. Mello SB, Farsky SH, Sannomiya P, Garcia-Leme J 1992. Inhibition of neutrophil chemotaxis and chemokinesis associated with a plasma protein in aging rats: selective depression of cell responses mediated by complement-derived chemoattractants. J Leukoc Biol 51: 46-52.
41. Metcalfe DD, Baram D, Mekori YA 1997. Mast cells. Physiol Rev 77: 1033-1079.
42. Mirel DB, Valdes AM, Lazzeroni LC, Reynolds RL, Erlich HA, Noble JA 2002. Association of IL4R haplotypes with type 1 diabetes. Diabetes 51: 3336-3341.
43. Mowat A, Baum J 1971. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 284: 621-627.
44. Muir A, Schatz DA, Maclaren NK 1992. The pathogenesis, prediction, and prevention of insulin-dependent diabetes mellitus. Endocrinol Metab Clin North Am 21: 199-219.
45. Olesen AB, Juul S, Birkebaek N, Thestrup-Pedersen K 2001. Association between atopic dermatitis and insulin-dependent diabetes mellitus: a case-control study. Lancet 357: 1749-1752.
46. Pipkorn U, Hammarlund A, Enerback L 1989. Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen-induced weal-and-flare response and a reduction in skin mast cell numbers and histamine content. Clin Exp Allergy 19: 19-25.
47. Ptak W, Rewicka M, Strzyzewska J, Kollat M 1983. Alleviation of IgE-mediated immune reactions in hypoinsulinaemic and hyperglycaemic mice. Clin Exp Immunol 52: 54-60.
48. Quan N, Ho E, La W, Tsai YH, Bray T 2001. Administration of NF-kappaB decoy inhibits pancreatic activation of NF-kappaB and prevents diabetogenesis by alloxan in mice. Faseb J 15: 1616-1618.
49. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, Cyopick P, Danska JS, Delovitch TL 1993. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 178: 87-99.
50. Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H 1982. Infection and diabetes: the case for glucose control. Am J Med 72: 439-450.
51. Rerup CC 1970. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 22: 485-518.
52. Romagnani S 1991. Human TH1 and TH2 subsets: doubt no more. Immunol Today 12: 256-257.
53. Roy M, Collier B, Roy A 1990. Hypothalamic-pituitary-adrenal axis dysregulation among diabetic outpatients. Psychiatry Res 31: 31-37.
54. Roy MS, Roy A, Brown S 1998. Increased urinary-free cortisol outputs in diabetic patients. J Diabetes Complications 12: 24-27
55. Schleimer RP 1993. An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol 45 (Suppl 1): S3-7; discussion S43-44.
56. Silva PMR, Martins MA, Lima MC, Alves AC, Diaz BL, Cordeiro RS 1992. Pharmacological modulation of the late eosinophilia induced by antigen in actively sensitized rats. Int Arch Allergy Immunol 98: 355-360.
57. Strauss DS 1984. Growth stimulatory actions of insulin in vitro and in vivo. Endocrine Review 5: 356-369.
58. Taskinen MR, Lahdenpera S, Syvanne M 1996. New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann Med 28: 335-340.
59. Tinkelman D, King S 1979. Severe asthma and volatile diabetes mellitus in the same patient: a treatment dilemma. J Allergy Clin Immunol 64: 223-226.
60. Tisch R, McDevitt H 1996. Insulin-dependent diabetes mellitus. Cell 85: 291-297.
61. Vianna EO, Garcia-Leme J 1995. Allergen-induced airway inflammation in rats. Role of insulin. Am J Respir Crit Care Med 151: 809-814.
62. Vlassara H, Brownlee M, Cerami A 1984. Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. J Exp Med 160: 197-207.
63. Wertman KF, Henney MR 1962. The effects of alloxan diabetes on phagocytosis and susceptibility to infection. J Immunol 89: 314-317.
64. Wood SC, Rao TD, Frey AB 1999. Multidose streptozotocin induction of diabetes in BALB/cBy mice induces a T cell proliferation defect in thymocytes which is reversible by interleukin-4. Cell Immunol 192: 1-12.
65. Yabe-Nishimura C 1998. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 50: 21-33.
66. Zimmet P, Alberti KG, Shaw J 2001. Global and societal implications of the diabetes epidemic. Nature 414: 782-787.